Citigroup
MPLT

Citigroup’s MapLight Therapeutics MPLT Stock Holding History

Citigroup’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19.5K Buy
960
+577
+151% +$10.3K ﹤0.01% 4828
2025
Q4 		$6.73K Buy
+383
New +$6.42K ﹤0.01% 5172

Other funds holding MPLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Citigroup's MPLT Position: Q1 2026 in Review

Citigroup increased its MapLight Therapeutics (MPLT) stake by 151% in Q1 2026, buying an estimated $10.3K and bringing the position to 960 shares worth $19.5K. The position accounts for ﹤0.01% of the portfolio, ranked #4828.

Citigroup first reported a position in MPLT in Q4 2025 and has held it in 2 quarters since. 81 funds tracked by Wall St. Rank hold MPLT as of Q1 2026.

  • Citigroup held 960 shares of MapLight Therapeutics worth $19.5K as of Q1 2026.
  • Citigroup bought 577 MapLight Therapeutics shares in Q1 2026, an estimated $10.3K.
  • MapLight Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #4828 holding.
  • Citigroup first reported a position in MapLight Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • 81 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.